Connect Biopharma Holdings Ltd ordinary shares CNTB

Morningstar Rating
$1.99 −0.07 (3.40%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CNTB is trading at a 271% premium.
Price
$1.99
Fair Value
$9.84
Uncertainty
Jcdm Xtbp
1-Star Price
$3.41
5-Star Price
$5.16
Economic Moat
Bctkm
Capital Allocation

News

Trading Information

Previous Close Price
$2.06
Day Range
$1.952.09
52-Week Range
$0.913.82
Bid/Ask
$1.96 / $2.43
Shares Outstanding
62.96M
Market Cap
$125.30M
Volume/Avg
256,078 / 288,776

Key Statistics

Price/Earnings (Normalized)
Price/Sales
509.13
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
64

Valuation

Metric
CNTB
Price/Earnings (Normalized)
Price/Book Value
3.12
Price/Sales
509.13
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
CNTB
Quick Ratio
2.86
Current Ratio
3.23
Interest Coverage
Quick Ratio
CNTB

Profitability

Metric
CNTB
Return on Assets (Normalized)
−84.45%
Return on Equity (Normalized)
−103.02%
Return on Invested Capital (Normalized)
−104.68%
Return on Assets
CNTB

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
FwlnxpnBrcrf$113B
Regeneron Pharmaceuticals Inc
REGN
FzyldscbNwvhbxm$64B
argenx SE ADR
ARGX
TvmhczxDgcc$56B
Alnylam Pharmaceuticals Inc
ALNY
CzsptbckkYrbpg$38B
Royalty Pharma PLC Class A
RPRX
GmmdrtzncnFmrctc$24B
BioNTech SE ADR
BNTX
SrdjbvzzYvk$23B
Incyte Corp
INCY
PkbybdwcYtxrq$22B
Moderna Inc
MRNA
HlsnjbxpbGjt$20B
Jazz Pharmaceuticals PLC
JAZZ
WrvhpsrHhzl$14B
BridgeBio Pharma Inc
BBIO
BqqzyfgzLfszd$13B

Sponsor Center